| Sr. No | Title of research project | Name of Principle investigator | Sanctioning/ Collaborating agency | Completed/Ongoing |
| 1 | A Multicenter, Randomized, Parallel-Group, 6- Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80ug Inhalation Aerosal (Cipla ltd) in comparison with the reference product, symbicort (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5ug per actuation) Inhalation Aerosol(Astra Zeneca, USA ), in Adult Asthma patients |
Dr. Sushama R Dugad
Dr. Ravindra Shinde |
Cipla Ltd,.India | Ongoing |
| Sr. No. | Year | Title of the Research | Name | Status |
| 1 | 2021-2022 | IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMME IMPLEMENTATION IN PATIENTS OF MEDICAL INTENSIVE CARE UNIT OF A TERTIARY CARE CENTRE | Dr. Komal Shah | Ongoing |
| Sr. No | Title of research project | Name of Principle investigator | Sanctioning/ Collaborating agency | Completed/Ongoing |
| 1 | Prospective, open label, multicentre, single arm, post marketing study for evaluation of safety and efficacy of Favipiravir in adult Indian patients with mild to moderate covid-19 disease | Dr Ravindra Shinde | Glenmark Ltd. | 2020-2021 |
| Sr. No | Title of research project | Name of Principle investigator | Sanctioning/ Collaborating agency | Completed/Ongoing | |
| 1 | Clinical trial- A randomized, open label, two way crossover study to compare inhalation flow profiles generated with medication free generic tiotropium bromide inhalation device of Cipla Ltd, India and SPIRIVA HANDIHALER device of Boehringer ingelheim pharmaceuticals, inc, USA in healthy adult subjects and adult subjects with moderate, sever and very severe chronic obstructive pulmonary disease (Crd/27)(the clinical study) | Dr. Gauri Kulkarni | Cipla ltd | Ongoing | |
| 2 | Prospective, open label, multicentre, single arm, post marketing study for evaluation of safety and efficacy of Favipiravir in adult Indian patients with mild to moderate covid-19 disease | Dr Ravindra Shinde | Glenmark ltd | Ongoing | |
- Research activity of Department:
| Sr. No. | Year | Title of the Research | Name | Status |
| 1 | 2019 | Outcome of multidrug Resistant Tuberculosis 5yr follow up study | Dr. Gauri Kulkarni
Dr. Nilesh Patil
|
Completed |
| 2 | 2019 | To Study Respiratory Manifestation in chronic Renal Failure Patients | Dr. G. S. Kulkarni
Dr. Nikhil Raj
|
Completed |
| 3 | 2019 | Study of Clinical Profile H1 N1 Swine flu influenza patients at a tertiary care center | Dr. R. M. Sundrani
Dr. G. S. Kulkarni Dr. Jaspreet Singh
|
Completed |
| 4 | 2019 | Study of Adverse Drug reactions Related to Pre XDR and XDR Tuberculosis on Bedaquline Drug within 14 days of Admission | Dr. S. R. Dugad
|
Completed |
| 5 | 2020 | Clinical Characteristics of Covid 19 (Sars-Cov-2) Patients at a Tertiary Health Care Centre | Dr. Ravindra Shinde
Dr. Chaitanya Kappagantu |
Ongoing |
| 6 | 2020 | Clinicoradiological Corelation In Covid 19 (Sars-Cov-2) Patients Admitted at Aa Tertiary Health Care Centre” | Dr. Ravindra Shinde , Dr. Jaspreet
|
Ongoing |
| 7 | 2020 | Clinical characteristics of asymptomatic patients of COVID 19 patients admitted in tertiary health care centre | Dr. Sushama Dugad, Dr. Siddhesh Bharadi | ongoing |
| 8 | 2021 | “Outcome of clinico radiological and sputum culture conversion of drug Resistant tuberculosis patient receiving bedaquiline regimen at end of 6 months At nodal drug resistance tuberculosis centre, Nashik” | Dr. Chaitanya Kappagantu
Dr Sushama R Dugad |
Ongoing |
| 9 | 2021 | Study of outcome of extra pulmonary drug resistant tuberculosis patient at nodal drug resistance tuberculosis center, Nashik | Dr. Chaitanya Kappagantu
Dr Ravindra Shinde |
Ongoing |
| 10 | 2021 | Prospective, open label, multicentre, single arm, post marketing study for evaluation of safety and efficacy of Favipiravir in adult Indian patients with mild to moderate covid-19 disease | Dr Ravindra Shinde | Ongoing |